MHB 036C
Alternative Names: MHB-036CLatest Information Update: 20 Nov 2025
At a glance
- Originator Minghui Pharmaceutical (Shanghai)
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer; Solid tumours
- Phase I/II Lung cancer
Most Recent Events
- 20 Nov 2025 Phase-I/II clinical trials in Lung cancer (Metastatic disease, Late-stage disease, Combination therapy) in China (IV) (NCT07229599)
- 30 Sep 2025 Phase-II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in China (IV) (NCT07130383)
- 20 May 2025 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Combination therapy) (IV)